The Phase I randomized, double-blind, placebo-controlled, multiple dose
escalation study will evaluate the safety and tolerability of ASN002 as
well as preliminary efficacy in subjects with moderate to severe atopic
“We are extremely pleased with the efficient execution of our strategy
to work on clinically validated targets and develop drugs that are
differentiated from the competition,” said Sandeep Gupta, PhD, Founder,
President and Chief Executive Officer at Asana BioSciences. Asana is
focused on the development of ‘Best-in-Class’ drugs designed to offer
significant benefit over the existing standards of care and address
unmet medical needs. “The successful filing of this IND enables a
broader development of ASN002 in autoimmune skin and other diseases and
reflects Asana’s expanded scope and capabilities, in addition to our
expertise in oncology and hematology drug development,” stated Dr.
Gupta. ASN002 is also being evaluated in a Phase I/II clinical trial in
patients with non-Hodgkin’s lymphoma and solid tumors.
Asana’s other lead molecules, ASN001 and ASN003, are in Phase I/II
clinical trials. ASN001, a novel and highly selective CYP17 inhibitor
that does not require prednisone co-administration, targets metastatic
castration resistant prostate cancer. ASN003 is a novel and highly
selective oral inhibitor of B-RAF and PI3 Kinase enzymes that is being
evaluated in patients with advanced solid tumors with RAF or PI3K
pathway alterations, e.g. melanoma, colon and lung cancer.
About Asana BioSciences, LLC
Asana BioSciences, LLC, an independent member of the Amneal Alliance of
Companies, is a research and development company based in Lawrenceville,
NJ, specializing in the discovery and development of new chemical and
biological entities. Asana’s portfolio consists of multiple early-stage
drug discovery and development candidates in a variety of therapeutic
areas, including oncology, pain, dermatology and autoimmune diseases.
Asana BioSciences, LLC